Microarray testing was done in two batches but we found no evidence for a batch effect in our analyses.
Family 9 had chromosome microarray testing, followed by reanalysis of exome data (Ambry Genetics, Santa Clara, CA).
Coulter, M. E. et al. Chromosomal microarray testing influences medical management.
Whether microarray testing will become a standard is still unclear.
Family 8 had chromosome microarray testing, followed by ES analysis limited to a specific phenotype-driven gene list provided by the ordering clinician that included TANGO2.
The window of opportunity for microarray testing might also be limited.
Insurance does not always pay for microarray testing since it is not considered the standard of care for prenatal testing.
Although gene expression profiling using microarray technology is widely used in research environments, adoption of microarray testing in clinical laboratories is currently limited.
Geng J, Picker J, Zheng Z, Zhang X, Wang J, Hisama F, Brown DW, Mullen MP, Harris D, Stoler J, Seman A, Miller DT, Fu Q, Roberts AE, Shen Y. Chromosome microarray testing for patients with congenital heart defects reveals novel disease causing loci and high diagnostic yield.
In the future, polymerase chain reaction assays, microarray testing, genomic analysis, and metabolic profiling will be accomplished in a rapid, portable, sensitive, and cost-efficient manner.
